Abeona Therapeutics Inc. (NASDAQ:ABEO) Given Average Recommendation of “Moderate Buy” by Analysts

Abeona Therapeutics Inc. (NASDAQ:ABEO) has been assigned an average recommendation of “Moderate Buy” from the five ratings firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $20.00.

Several equities research analysts have recently issued reports on ABEO shares. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Abeona Therapeutics in a report on Tuesday, March 10th. Weiss Ratings reissued a “sell (d+)” rating on shares of Abeona Therapeutics in a research note on Wednesday, January 21st. Oppenheimer restated an “outperform” rating on shares of Abeona Therapeutics in a report on Monday, March 9th. Finally, Wall Street Zen downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th.

Abeona Therapeutics Stock Down 3.8%

Shares of ABEO stock opened at $4.76 on Friday. The company’s fifty day simple moving average is $5.12 and its two-hundred day simple moving average is $5.27. Abeona Therapeutics has a 52 week low of $3.93 and a 52 week high of $7.54. The stock has a market cap of $257.94 million, a P/E ratio of 3.87 and a beta of 1.13. The company has a quick ratio of 9.53, a current ratio of 9.74 and a debt-to-equity ratio of 0.06.

Trending Headlines about Abeona Therapeutics

Here are the key news stories impacting Abeona Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $20 price target on ABEO, signaling strong long‑term upside relative to the current share price. HC Wainwright Reaffirms Buy
• Neutral Sentiment: Multiple March short‑interest notices report either a large increase or contain erroneous/zero values (0 shares, NaN changes), creating ambiguity around current short pressure; the data file appears unreliable and should be interpreted cautiously. MarketBeat ABEO Page
• Negative Sentiment: HC Wainwright materially lowered EPS estimates across multiple quarters and for FY2026 (examples: Q1 2026 to ($0.31) from ($0.23), Q2 to ($0.27) from ($0.21), Q3 to ($0.20) from ($0.02), and FY2026 to ($0.97) from ($0.41)), indicating the analyst now expects weaker near‑term results — a primary driver of downward pressure on the stock. HC Wainwright Estimates (via MarketBeat)

Insider Transactions at Abeona Therapeutics

In related news, Director Leila Alland sold 18,065 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $5.09, for a total value of $91,950.85. Following the sale, the director owned 173,614 shares in the company, valued at approximately $883,695.26. The trade was a 9.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Joseph Walter Vazzano sold 18,666 shares of the stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $5.33, for a total transaction of $99,489.78. Following the transaction, the chief financial officer owned 568,560 shares of the company’s stock, valued at $3,030,424.80. This trade represents a 3.18% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 209,605 shares of company stock valued at $1,101,300 in the last 90 days. Company insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Ameritas Investment Partners Inc. purchased a new position in Abeona Therapeutics in the second quarter worth about $25,000. Legal & General Group Plc bought a new stake in Abeona Therapeutics during the second quarter worth approximately $27,000. Russell Investments Group Ltd. purchased a new stake in Abeona Therapeutics during the third quarter valued at approximately $37,000. Truvestments Capital LLC raised its position in Abeona Therapeutics by 191.4% during the fourth quarter. Truvestments Capital LLC now owns 10,307 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 6,770 shares during the period. Finally, Legato Capital Management LLC bought a new stake in shares of Abeona Therapeutics in the 3rd quarter valued at approximately $57,000. Institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.